2022
Oxalate homeostasis
Ermer T, Nazzal L, Tio M, Waikar S, Aronson P, Knauf F. Oxalate homeostasis. Nature Reviews Nephrology 2022, 19: 123-138. PMID: 36329260, PMCID: PMC10278040, DOI: 10.1038/s41581-022-00643-3.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsKidney diseaseOxalate homeostasisAnti-inflammatory medicationsChronic kidney diseaseKidney replacement therapySudden cardiac deathProgressive kidney diseaseOutlook of patientsOxalate nephropathyCardiovascular complicationsSystemic inflammationCardiac deathReplacement therapySecondary hyperoxaluriaKidney failureElevated plasmaConsequent impairmentNovel therapeuticsPatientsDiseaseEffective elimination strategiesEndogenous sourcesHomeostasisElimination strategyExcretion
2013
Dabigatran and Kidney Disease: A Bad Combination
Knauf F, Chaknos CM, Berns JS, Perazella MA. Dabigatran and Kidney Disease: A Bad Combination. Clinical Journal Of The American Society Of Nephrology 2013, 8: 1591-1597. PMID: 23868901, PMCID: PMC3805067, DOI: 10.2215/cjn.01260213.Peer-Reviewed Original ResearchConceptsAnticoagulant effectPharmacokinetic profileOral direct thrombin inhibitorContinuous renal replacement therapyRoutine laboratory monitoringSerious bleeding eventsHigh bleeding riskReduced kidney functionRenal replacement therapyDirect thrombin inhibitorDrug Administration approvalLaboratory monitoring testsBleeding eventsBleeding riskSerious bleedingThromboembolic complicationsDose adjustmentHemodialysis cathetersKidney functionKidney diseaseReplacement therapyLaboratory monitoringAdministration approvalClinical indicationsDrug levels